ClinicalTrials.Veeva
Menu

Find clinical trials for Melanoma in Durham, NC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Renal Cell Carcinoma
Lung Cancer
Squamous Cell Carcinoma

Melanoma trials near Durham, NC, USA:

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Neoadjuvant/adjuvant IDE196 (darovasertib) in patients with primary uveal melanoma...

Enrolling
Uveal Melanoma
Drug: Darovasertib

Phase 2

Ideaya Biosciences

Durham, North Carolina, United States and 22 other locations

efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma...

Enrolling
Ocular Melanoma
Choroidal Melanoma
Device: Suprachoroidal Microinjector
Drug: Sham Treatment

Phase 3

Aura Biosciences
Aura Biosciences

Durham, North Carolina, United States and 37 other locations

To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investig...

Active, not recruiting
Uveal Melanoma
Biological: IMCgp100
Biological: Pembrolizumab

Phase 2

Immunocore
Immunocore

Durham, North Carolina, United States and 55 other locations

Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments.This study will evaluate the safety and effects of...

Active, not recruiting
Metastatic Uveal Melanoma
Metastatic Ocular Melanoma
Combination Product: Melphalan (3 mg/kg IBW) with Hepatic Delivery System (HDS)

Phase 3

Delcath Systems

Durham, North Carolina, United States and 4 other locations

antigen (HLA)-A\*02:01 negative participants with metastatic uveal melanoma (MUM) who will be randomized to receive either IDE196 + crizotin...

Enrolling
Metastatic Uveal Melanoma
Drug: IDE196
Drug: Nivolumab

Phase 2, Phase 3

Ideaya Biosciences

Durham, North Carolina, United States and 64 other locations

of up to 2 dose selection cohorts to evaluate the safety and tolerability of dapansutrile + pembrolizumab in patients with PD-1 resistant melanoma...

Enrolling
Melanoma
Drug: Dapansutrile
Drug: Pembrolizumab

Phase 1, Phase 2

April Salama, M.D.

Durham, North Carolina, United States

to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...

Active, not recruiting
Melanoma
Biological: Nivolumab
Biological: Nivolumab + Relatlimab Fixed Dose Combination

Phase 3

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Durham, North Carolina, United States and 171 other locations

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.Part 2 is phase II design of APG-115 at recommended phase 2...

Enrolling
Mucosal Melanoma
Melanoma
Drug: APG-115+Pembrolizumab

Phase 1, Phase 2

Ascentage Pharma Group
Ascentage Pharma Group

Durham, North Carolina, United States and 19 other locations

administered to participants with unresectable or metastatic melanoma.The study is divided into two phases: Phase 2 and Phase 3.The primary ...

Active, not recruiting
Advanced Melanoma
Melanoma
Drug: Nivolumab
Drug: CMP-001

Phase 2, Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Durham, North Carolina, United States and 19 other locations

be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on either pembrolizumab o...

Active, not recruiting
Stage III/IV Melanoma
Biological: Pembrolizumab
Biological: tavokinogene telseplasmid

Phase 2

OncoSec Medical

Durham, North Carolina, United States and 32 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems